This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

NeoStem To Present At Multiple October Conferences

Stocks in this article: NBS

NEW YORK, Sept. 30, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple upcoming conferences in October.

2013 RAPS (Regulatory Affairs Professional Society): The Regulatory Convergence

  • Date and Time: Tuesday, October 1, 3:00 PM EDT
  • Venue: John B. Hynes Veterans Memorial Convention Center, Boston, MA
  • Session: Regulatory Requirements for Cell Therapy Tools
  • Speaker: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, PCT

U.S. Food and Drug Administration (FDA) Public Workshop: Synergizing Efforts in Standards Development for Cellular Therapies and Regenerative Medicine Products

  • Date and Time: Monday, October 7, 11:20 AM EDT
  • Venue: FDA White Oak Campus, Silver Spring, MD
  • Session: Professional Societies, Industry Organizations, and Standards Related Organizations
  • Speaker: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, PCT

BIO Investor Forum San Francisco

  • Date and Time: Wednesday, October 9, 10:30 AM PDT
  • Venue: The Palace Hotel, San Francisco, CA
  • Session: Company Presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO, NeoStem

Stem Cell Meeting on the Mesa

  • Venue: Estancia La Jolla Hotel & Spa, La Jolla, CA
  • Session #1 Date and Time: Tuesday, October 15, 8:45 AM PDT
  • Session#1: Regulatory Challenges & Strategies For Regen Med Companies
  • Speaker #1: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, PCT
  • Session #2 Date and Time: Tuesday, October 15, 11:15 AM PDT
  • Session #2: Company Presentation, NeoStem
  • Speaker #2: Robin L. Smith, MD, MBA, Chairman and CEO, NeoStem
  • Session #3 Date and Time: Tuesday, October 15, 3:00 PM PDT
  • Session #3: Company Presentation, PCT
  • Speaker #3: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, PCT

IBC's 3 rd Annual Cell Therapy Bioprocessing

  • Venue: Bethesda Marriott, Bethesda, MD
  • Session #1 Date and Time: Monday, October 21, 8:45 AM EDT
  • Session #1: Challenges and Future Directions for Commercial Scale Patient-Specific Production
  • Speaker #1: Brian Hampson, Senior Director, Innovation and Engineering
  • Session #2 Date and Time: Monday, October 21, 1:25 PM EDT
  • Session #2: Process Development for Commercial Success
  • Speaker #2: Robert Shaw, Vice President, Commercial Development

New York Society of Security Analysts' 17th Annual Life Science Conference

  • Date and Time: Wednesday, October 30, 10:00 EDT
  • Venue: NYSSA Conference Facilities , New York, NY
  • Session: Company Presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO

A bout NeoStem, Inc.

NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs